Banks, W.A., M.J. During, and M.L. Niehoff Brain uptake of the glucagon-like peptide-1 antagonist exendin (9-39) after intranasal administration. J Pharmacol Exp Ther, 2004, vol. 309(2), pp. 469-475.

has been cited by the following article:

• TITLE: Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles

  AUTHORS: I.G. Kondrasheva, T.A. Antipova, G.G. Barsegyan, P.Ye. Gambaryan, A.A. Guseva, A.A. Kamensky

  KEYWORDS: Nanopaticls; L-DOPA; Nasal Administration; Parkinson’s Disease

  JOURNAL NAME: Engineering, Vol.4 No.10B, January 16, 2013

  ABSTRACT: Inclusion of L-DOPA, the standard Parkinson’s disease medication, into polymeric particles (PLGA) results in optimization the drug metabolism and increasing its bioavailability, significantly increases of physical endurance, better coordination and lower anxiety in Wistar rats, when chronically administered nasally.